بدائل البحث:
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
significant changes » significant challenge (توسيع البحث)
changes decrease » larger decrease (توسيع البحث), largest decrease (توسيع البحث), change increases (توسيع البحث)
significant decrease » significant increase (توسيع البحث), significantly increased (توسيع البحث)
significant changes » significant challenge (توسيع البحث)
changes decrease » larger decrease (توسيع البحث), largest decrease (توسيع البحث), change increases (توسيع البحث)
-
2041
-
2042
-
2043
-
2044
-
2045
-
2046
-
2047
Age-related correlation of PBMCs percentages in comparison between males and females.
منشور في 2024الموضوعات: -
2048
-
2049
Mass spectrometric analyses for crystallins.
منشور في 2025"…Previous <i>in-vitro</i> studies of recombinant βA3ΔG91 showed defective folding, decreased solubility, and aberrant oligomerization of βA3ΔG91 with other crystallins. …"
-
2050
RNA-seq data showing top 15 downregulated genes.
منشور في 2025"…Previous <i>in-vitro</i> studies of recombinant βA3ΔG91 showed defective folding, decreased solubility, and aberrant oligomerization of βA3ΔG91 with other crystallins. …"
-
2051
RNA-seq data showing top 15 upregulated genes.
منشور في 2025"…Previous <i>in-vitro</i> studies of recombinant βA3ΔG91 showed defective folding, decreased solubility, and aberrant oligomerization of βA3ΔG91 with other crystallins. …"
-
2052
Study flow chart.
منشور في 2025"…The risk of ADCs increased from stage 2 (OR: 0.46, p-value: 0.03; 95% CI: 0.23–0.91) to stage 3 (OR: 1.13; p-value: 0.66; 95% CI: 0.65–1.97) but this was not statistically significant. The risk of ADCs decreased with increasing ART duration (<i>P</i> value < 0.05).…"
-
2053
Bar graph showing proportion of NADCs.
منشور في 2025"…The risk of ADCs increased from stage 2 (OR: 0.46, p-value: 0.03; 95% CI: 0.23–0.91) to stage 3 (OR: 1.13; p-value: 0.66; 95% CI: 0.65–1.97) but this was not statistically significant. The risk of ADCs decreased with increasing ART duration (<i>P</i> value < 0.05).…"
-
2054
Baseline characteristics of study participants.
منشور في 2025"…The risk of ADCs increased from stage 2 (OR: 0.46, p-value: 0.03; 95% CI: 0.23–0.91) to stage 3 (OR: 1.13; p-value: 0.66; 95% CI: 0.65–1.97) but this was not statistically significant. The risk of ADCs decreased with increasing ART duration (<i>P</i> value < 0.05).…"
-
2055
-
2056
-
2057
-
2058
-
2059
-
2060